Experienced in Urothelial Cancer

Dr. Krishna S. Gunturu

Hematology Oncology | Hematology | Oncology
The Hospital Of Central Connecticut At New Britain General And Bradley
183 N Mountain Rd, 
New Britain, CT 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Urothelial Cancer
The Hospital Of Central Connecticut At New Britain General And Bradley
183 N Mountain Rd, 
New Britain, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Krishna Gunturu is a Hematologist Oncology specialist and a Hematologist in New Britain, Connecticut. Dr. Gunturu is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Liver Embolization.

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NH
Hospital Affiliations
Lahey Hospital & Medical Center, Burlington
The Hospital Of Central Connecticut
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

THE HOSPITAL OF CENTRAL CONNECTICUT AT NEW BRITAIN GENERAL AND BRADLEY
183 N Mountain Rd, New Britain, CT 06053
Other Locations
THE HOSPITAL OF CENTRAL CONNECTICUT AT NEW BRITAIN GENERAL AND BRADLEY
100 Grand St, New Britain, CT 06052

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

18 Total Publications

Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 08, 2024
Similar Doctors
Elite in Urothelial Cancer
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology
Elite in Urothelial Cancer
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology

Yale University

5 Perryridge Rd, 
Greenwich, CT 
 (60.8 miles away)
203-863-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Petrylak is an Oncologist and a Hematologist Oncology provider in Greenwich, Connecticut. Dr. Petrylak is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, Orchiectomy, and Gamma Knife Radiosurgery.

Distinguished in Urothelial Cancer
Dr. Harold Tara
Oncology | Hematology | Hematology Oncology
Distinguished in Urothelial Cancer
Dr. Harold Tara
Oncology | Hematology | Hematology Oncology

Yale University

5520 Park Ave, 
Trumbull, CT 
 (37.7 miles away)
203-337-8700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Harold Tara is an Oncologist and a Hematologist in Trumbull, Connecticut. Dr. Tara is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Familial Prostate Cancer, and Colorectal Cancer.

Distinguished in Urothelial Cancer
Dr. Jason R. Haldas
Hematology Oncology | Hematology | Oncology
Distinguished in Urothelial Cancer
Dr. Jason R. Haldas
Hematology Oncology | Hematology | Oncology

Northeast Medical Group Inc

230 Waterford Pkwy S, 
Waterford, CT 
 (39.3 miles away)
860-444-3744
Languages Spoken:
English
See accepted insurances

Jason Haldas is a Hematologist Oncology specialist and a Hematologist in Waterford, Connecticut. Dr. Haldas is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Anaplastic Large Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, and Small Cell Lung Cancer (SCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunturu's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile